Polyagonist medications that stimulate several gut-brain pathways have the potential to revolutionize the treatment of T2DM and obesity
Indications in the market include Type 2 Diabetes at 5.0 to 20.0 USD Billion, Obesity at 3.0 to 12.0 USD Billion, and Cardiovascular Diseases at 2.77 to 10.0 USD Billion
Studies examining whether combined effects are additive or synergistic would address this gap
The freeze-dried format helps maintain product integrity during storage and transportation
Pharmadevice collaborations, analytical innovation, and sustainable design will be key to tackle the growing device bottleneck The rapid global adoption of GLP-1 based therapies, developed for diabetes and now also used for weight management, has reshaped the pharma landscape
they include the superoxide anion (O 2 ), hydrogen peroxide (H 2 O 2 ), singlet oxygen ( 1 O 2 ) and the hydroxyl radical (HO )